Last reviewed · How we verify
Docetaxel, Carboplatin and Trastuzumab
Docetaxel, Carboplatin and Trastuzumab is a Small molecule drug developed by Cancer Trials Ireland. It is currently in Phase 2 development.
At a glance
| Generic name | Docetaxel, Carboplatin and Trastuzumab |
|---|---|
| Sponsor | Cancer Trials Ireland |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (PHASE3)
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (PHASE3)
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (PHASE2)
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (PHASE1)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, Carboplatin and Trastuzumab CI brief — competitive landscape report
- Docetaxel, Carboplatin and Trastuzumab updates RSS · CI watch RSS
- Cancer Trials Ireland portfolio CI
Frequently asked questions about Docetaxel, Carboplatin and Trastuzumab
What is Docetaxel, Carboplatin and Trastuzumab?
Docetaxel, Carboplatin and Trastuzumab is a Small molecule drug developed by Cancer Trials Ireland.
Who makes Docetaxel, Carboplatin and Trastuzumab?
Docetaxel, Carboplatin and Trastuzumab is developed by Cancer Trials Ireland (see full Cancer Trials Ireland pipeline at /company/cancer-trials-ireland).
What development phase is Docetaxel, Carboplatin and Trastuzumab in?
Docetaxel, Carboplatin and Trastuzumab is in Phase 2.